Eukaryotic translation initiation factor 4E
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain A； UniProt 1–217 | Not recorded | UNX UNKNOWN LIGAND × 6 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；289 K；20% PEG-3350, 0.2 M diammonium citrate, vapor diffusion, temperature 289K | Resolution 2.10 Å R-free 0.260 |
| 2 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain B； UniProt 1–217 | Not recorded | UNX UNKNOWN LIGAND × 4 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；289 K；20% PEG-3350, 0.2 M diammonium citrate, vapor diffusion, temperature 289K | Resolution 2.10 Å R-free 0.260 |
| 3 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain C； UniProt 1–217 | Not recorded | UNX UNKNOWN LIGAND × 3 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；289 K；20% PEG-3350, 0.2 M diammonium citrate, vapor diffusion, temperature 289K | Resolution 2.10 Å R-free 0.260 |
| 4 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain D； UniProt 1–217 | Not recorded | UNX UNKNOWN LIGAND × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；289 K；20% PEG-3350, 0.2 M diammonium citrate, vapor diffusion, temperature 289K | Resolution 2.10 Å R-free 0.260 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 3TF2 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1IPB CRYSTAL STRUCTURE OF EUKARYOTIC INITIATION FACTOR 4E COMPLEXED WITH 7-METHYL GPPPA Deposited 2001-05-08 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–217（217 aa）
|
Not recorded | GTA P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å R-free 0.229 |
| 1IPC CRYSTAL STRUCTURE OF EUKARYOTIC INITIATION FACTOR 4E COMPLEXED WITH 7-METHYL GTP Deposited 2001-05-08 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–217（217 aa）
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å R-free 0.228 |
| 1WKW Crystal structure of the ternary complex of eIF4E-m7GpppA-4EBP1 peptide Deposited 2004-06-10 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
27–217（191 aa）
Fragment：RESIDUES 27-217
|
Not recorded | GTA P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；PEG 4000, isopropanol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.270 |
| 2GPQ Cap-free structure of eIF4E suggests basis for its allosteric regulation Deposited 2006-04-18 | Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–217（217 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；293 K；Ionic strength (raw mmCIF value) 100 mM NaCl；Pressure ambient
NMR sample composition
0.3mM eIF4E U-98% 15N, U-13C;
50mM phosphate buffer; 100mM NaCl; 1mM DTT; 0.02% NaN3; 90% H2O, 10% D2O | 50mM phosphate buffer; 100mM NaCl; 1mM DTT; 0.02% NaN3; 90% H2O, 10% D2O
NMR sample composition
0.3mM eIF4E U-98% 15N, U-95% D;
50mM phosphate buffer; 100mM NaCl; 1mM DTT; 0.02% NaN3; 90% H2O, 10% D2O | 50mM phosphate buffer; 100mM NaCl; 1mM DTT; 0.02% NaN3; 90% H2O, 10% D2O
|
Resolution not provided |
| 2V8W Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives Deposited 2007-08-16 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7
|
Resolution 2.30 Å R-free 0.243 |
| 2V8W Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives Deposited 2007-08-16 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7
|
Resolution 2.30 Å R-free 0.243 |
| 2V8X Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives Deposited 2007-08-16 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | MGQ 7-BENZYL GUANINE MONOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；25% PEG 6000, 7% AMMONIUM SULPHATE, 100MM HEPES-KOH PH 7.0
|
Resolution 2.30 Å R-free 0.259 |
| 2V8X Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives Deposited 2007-08-16 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
1–217（217 aa）
|
Not recorded | MGQ 7-BENZYL GUANINE MONOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；25% PEG 6000, 7% AMMONIUM SULPHATE, 100MM HEPES-KOH PH 7.0
|
Resolution 2.30 Å R-free 0.259 |
| 2V8Y Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives Deposited 2007-08-16 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | MGV P-FLUORO-7-BENZYL GUANINE MONOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；25% PEG 6000, 7% AMMONIUM SULPHATE, 100MM HEPES-KOH PH 7.0
|
Resolution 2.10 Å R-free 0.250 |
| 2V8Y Crystallographic and mass spectrometric characterisation of eIF4E with N7-cap derivatives Deposited 2007-08-16 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
1–217（217 aa）
|
Not recorded | MGV P-FLUORO-7-BENZYL GUANINE MONOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；25% PEG 6000, 7% AMMONIUM SULPHATE, 100MM HEPES-KOH PH 7.0
|
Resolution 2.10 Å R-free 0.250 |
| 2W97 Crystal Structure of eIF4E Bound to Glycerol and eIF4G1 peptide Deposited 2009-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–217（217 aa）
Chain B
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 PGE TRIETHYLENE GLYCOL × 1 SO4 SULFATE ION × 4 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；60% AMMONIUM SULPHATE, 100MM TRIS-HCL PH 8.0, 1% PEG400
|
Resolution 2.29 Å R-free 0.239 |
| 3AM7 Crystal structure of the ternary complex of eIF4E-M7GTP-4EBP2 peptide Deposited 2010-08-17 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
27–217（191 aa）
Fragment：UNP RESIDUES 27-217
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；291 K；20% PEG-MME 2000, 0.1M MES, 0.2M ammonium sulfate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K
|
Resolution 2.20 Å R-free 0.268 |
| 3U7X Crystal structure of the human eIF4E-4EBP1 peptide complex without cap Deposited 2011-10-14 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | SO4 SULFATE ION × 1 UNX UNKNOWN LIGAND × 9 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；1:1 of (protein stock: 0.0004 M eif4e, 0.001 M 4epb1, 0.004 M ribavirin, 0.02 HEPES, 0.1 M potassium chloride, 0.001 tcep, ph 7.3):(reservoir: 2 M ammonium sulfate, 2% Peg-400, 0.1 M sodium HEPES), vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.10 Å R-free 0.224 |
| 3U7X Crystal structure of the human eIF4E-4EBP1 peptide complex without cap Deposited 2011-10-14 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–217（217 aa）
|
Not recorded | SO4 SULFATE ION × 3 UNX UNKNOWN LIGAND × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；1:1 of (protein stock: 0.0004 M eif4e, 0.001 M 4epb1, 0.004 M ribavirin, 0.02 HEPES, 0.1 M potassium chloride, 0.001 tcep, ph 7.3):(reservoir: 2 M ammonium sulfate, 2% Peg-400, 0.1 M sodium HEPES), vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.10 Å R-free 0.224 |
| 3U7X Crystal structure of the human eIF4E-4EBP1 peptide complex without cap Deposited 2011-10-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
1–217（217 aa）
Chain B
1–217（217 aa）
|
Not recorded | SO4 SULFATE ION × 4 UNX UNKNOWN LIGAND × 20 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；1:1 of (protein stock: 0.0004 M eif4e, 0.001 M 4epb1, 0.004 M ribavirin, 0.02 HEPES, 0.1 M potassium chloride, 0.001 tcep, ph 7.3):(reservoir: 2 M ammonium sulfate, 2% Peg-400, 0.1 M sodium HEPES), vapor diffusion, sitting drop, temperature 291K
|
Resolution 2.10 Å R-free 0.224 |
| 4AZA Improved eIF4E binding peptides by phage display guided design. Deposited 2012-06-25 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5；20% PEG 5000 MME, 100 MM BISTRIS PH 6.5.
|
Resolution 2.16 Å R-free 0.279 |
| 4AZA Improved eIF4E binding peptides by phage display guided design. Deposited 2012-06-25 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5；20% PEG 5000 MME, 100 MM BISTRIS PH 6.5.
|
Resolution 2.16 Å R-free 0.279 |
| 4BEA Crystal Structure of eIF4E in Complex with a Stapled Peptide Derivative Deposited 2013-03-07 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；18-26% OF POLYETHYLENE GLYCOL 3350, 0.01-02M AMMONIUM SULPHATE AND 100MM BIS-TRIS AT PH 5.5
|
Resolution 2.57 Å R-free 0.266 |
| 4DT6 Co-crystal structure of eIF4E with inhibitor Deposited 2012-02-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–217（217 aa）
|
Not recorded | 6LI 7-[2-(4-chlorophenoxy)ethyl]guanosine 5'-(dihydrogen phosphate) × 1 GOL GLYCEROL × 1 EDO 1,2-ETHANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；The purified protein which contained 100 uM m7-GTP was concentrated to about 7 mg/mL in 20 mM Hepes, pH 7.6, 100 mM KCl, 1mM DTT, and 0.1 mM EDTA for crystallization. The m7-GTP-bound eIF4e protein was crystallized with 1:1 ratio of protein solution to reservoir solution of 17-20% PEG-3350 and 0.1-0.4M Na formate, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.267 |
| 4DUM Co-crystal structure of eIF4E with inhibitor Deposited 2012-02-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–217（217 aa）
|
Not recorded | HLI (4-{7-[2-(4-chlorophenoxy)ethyl]-2-(methylamino)-6-oxo-6,7-dihydro-1H-purin-8-yl}phenyl)phosphonic acid × 1 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；The purified protein which contained 100 uM m7-GTP was then concentrated to about 7 mg/mL in 20 mM Hepes, pH7.6, 100 mM KCl, 1mM DTT, 0.1 mM EDTA for crystallization. The m7-GTP-bound eIF4e protein was crystallized with 1:1 ratio of protein solution to reservoir solution of 17-20% PEG-3350 and 0.1-0.4M Na formate, VAPOR DIFFUSION, SITTING DROP, temperature 289K
|
Resolution 2.95 Å R-free 0.271 |
| 4TPW The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G Deposited 2014-06-09 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 33R (2E)-2-{2-[(4P)-4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene}-3-(2-nitrophenyl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；PEG 4000 10-20%, 100mM MES pH 6.5, 10% IPN
|
Resolution 1.50 Å R-free 0.193 |
| 4TPW The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G Deposited 2014-06-09 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；PEG 4000 10-20%, 100mM MES pH 6.5, 10% IPN
|
Resolution 1.50 Å R-free 0.193 |
| 4TQB The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G Deposited 2014-06-10 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 34K (2E)-2-{2-[4-(4-bromophenyl)-1,3-thiazol-2-yl]hydrazinylidene}-3-(2-nitrophenyl)propanoic acid × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；PEG 4000 12-20%, 100mM MES pH 6.5, 10% IPN
|
Resolution 1.59 Å R-free 0.211 |
| 4TQB The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G Deposited 2014-06-10 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；PEG 4000 12-20%, 100mM MES pH 6.5, 10% IPN
|
Resolution 1.59 Å R-free 0.211 |
| 4TQC The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G Deposited 2014-06-10 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | M7G 7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE × 1 34J (2S)-3-(4-amino-3-nitrophenyl)-2-{2-[(4P)-4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]hydrazin-1-yl}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；290 K；PEG 4000 12-20%, 100mM MES pH 8.5, 10% IPN
|
Resolution 1.80 Å R-free 0.194 |
| 4TQC The co-complex structure of the translation initiation factor eIF4E with the inhibitor 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G Deposited 2014-06-10 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | M7G 7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；290 K；PEG 4000 12-20%, 100mM MES pH 8.5, 10% IPN
|
Resolution 1.80 Å R-free 0.194 |
| 4UED Complex of human eIF4E with the 4E binding protein 4E-BP1 Deposited 2014-12-16 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
36–217（182 aa）
Fragment：RESIDUES 36-217
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；0.03M EACH DIETHYLENE GLYCOL, TRIETHYLENE GLYCOL, TETRAETHYLENE GLYCOL, PENTAETHYLENE GLYCOL, 0.1M BICINE/TRIZMA BASE PH 8.5, 12.5% PEG1000, 12.5% PEG3350, 12.5% MPD
|
Resolution 1.75 Å R-free 0.237 |
| 5EHC Co-crystal structure of eIF4E with nucleotide mimetic inhibitor. Deposited 2015-10-28 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | 5NX 3-[[(2~{R},3~{S},4~{R},5~{R})-5-[2-azanyl-7-[(3-chlorophenyl)methyl]-6-oxidanylidene-1~{H}-purin-7-ium-9-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methylamino]-4-oxidanyl-cyclobut-3-ene-1,2-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；21-31% PEG 8000, 1???3% (NH4)2SO4, 100 mM HEPES, pH 7.5, 1 round of seeding
|
Resolution 2.40 Å R-free 0.264 |
| 5EI3 Co-crystal structure of eIF4E with nucleotide mimetic inhibitor. Deposited 2015-10-29 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | 5O8 ~{N}-[[(2~{R},3~{S},4~{R},5~{R})-5-[2-azanyl-6-oxidanylidene-7-(phenylmethyl)-1~{H}-purin-7-ium-9-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl]-1,1,1-tris(fluoranyl)methanesulfonamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；21-31% PEG 8000, 1???3% (NH4)2SO4, 100 mM HEPES, pH 7.5, 1 round of seeding
|
Resolution 1.71 Å R-free 0.187 |
| 5EIR Co-crystal structure of eIF4E with nucleotide mimetic inhibitor. Deposited 2015-10-30 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | 5O8 ~{N}-[[(2~{R},3~{S},4~{R},5~{R})-5-[2-azanyl-6-oxidanylidene-7-(phenylmethyl)-1~{H}-purin-7-ium-9-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl]-1,1,1-tris(fluoranyl)methanesulfonamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；21-31% PEG 8000, 1???3% (NH4)2SO4, 100 mM HEPES, pH 7.5, 1 round of seeding.
Crystals replaced in to above conditions without (NH4)2SO4 prior to freezing.
|
Resolution 2.69 Å R-free 0.272 |
| 5EKV Co-crystal structure of eIF4E with nucleotide mimetic inhibitor. Deposited 2015-11-04 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | 5PQ 3-[[(2~{R},3~{S},4~{R},5~{R})-5-(2-azanyl-7-methyl-6-oxidanylidene-1~{H}-purin-7-ium-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methylamino]-4-oxidanyl-cyclobut-3-ene-1,2-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；21-31% PEG 8000, 1-3% (NH4)2SO4, 100 mM HEPES, pH 7.5, 1 round of seeding
|
Resolution 3.61 Å R-free 0.342 |
| 5EKV Co-crystal structure of eIF4E with nucleotide mimetic inhibitor. Deposited 2015-11-04 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
1–217（217 aa）
|
Not recorded | 5PQ 3-[[(2~{R},3~{S},4~{R},5~{R})-5-(2-azanyl-7-methyl-6-oxidanylidene-1~{H}-purin-7-ium-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methylamino]-4-oxidanyl-cyclobut-3-ene-1,2-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；21-31% PEG 8000, 1-3% (NH4)2SO4, 100 mM HEPES, pH 7.5, 1 round of seeding
|
Resolution 3.61 Å R-free 0.342 |
| 5GW6 Water-Bridge Mediates Recognition of mRNA Cap in eIF4E Deposited 2016-09-08 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
23–217（195 aa）
|
Mutation：E105A, K106A, K108A | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5；289 K；20% PEG 5000 MME, 100MM TRIS BIS PH 5.0, 0.05M AMMONIUM SULPHATE
|
Resolution 1.97 Å R-free 0.228 |
| 5T46 Crystal structure of the human eIF4E-eIF4G complex Deposited 2016-08-29 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.25；293 K；0.1 M Hepes pH 7.25, 25% w/v PEG 6000
|
Resolution 1.53 Å R-free 0.162 |
| 5T46 Crystal structure of the human eIF4E-eIF4G complex Deposited 2016-08-29 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
1–217（217 aa）
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.25；293 K；0.1 M Hepes pH 7.25, 25% w/v PEG 6000
|
Resolution 1.53 Å R-free 0.162 |
| 5ZJY Stapled-peptides tailored against initiation of translation Deposited 2018-03-22 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；30%(W/V) PEG 6000, 0.1M Na-Hepes pH6.5
|
Resolution 1.59 Å R-free 0.216 |
| 5ZJZ Stapled-peptides tailored against initiation of translation Deposited 2018-03-22 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；12.5%(w/v) PEG20000, 20%(w/v) PEG MME 550, 0.1M MES/imidazole pH 6.5
|
Resolution 1.67 Å R-free 0.212 |
| 5ZK5 Stapled-peptides tailored against initiation of translation Deposited 2018-03-23 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
28–217（190 aa）
|
Not recorded | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；30%(w/v) PEG6000, 0.1M Na-Hepes pH 6.5
|
Resolution 2.25 Å R-free 0.268 |
| 5ZK7 Stapled-peptides tailored against initiation of translation Deposited 2018-03-23 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 IOD IODIDE ION × 4 GOL GLYCEROL × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；0.2M Potassium Iodide, 0.1M MES/Imidazole pH6.5, 25%(wv) PEG4000
|
Resolution 2.12 Å R-free 0.270 |
| 5ZK7 Stapled-peptides tailored against initiation of translation Deposited 2018-03-23 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
28–217（190 aa）
Fragment：UNP residues 28-217
|
Not recorded | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 IOD IODIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；0.2M Potassium Iodide, 0.1M MES/Imidazole pH6.5, 25%(wv) PEG4000
|
Resolution 2.12 Å R-free 0.270 |
| 5ZK9 Stapled-peptides tailored against initiation of translation Deposited 2018-03-23 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
28–217（190 aa）
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 PEG DI(HYDROXYETHYL)ETHER × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；12.5% pEG1000 w/v, 12.5% PEG3350 w/v, 12.5% MPD w/v, 0.1M MES/imidazole pH 6.5
|
Resolution 1.76 Å R-free 0.211 |
| 5ZML Stapled-peptides tailored against initiation of translation Deposited 2018-04-04 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
27–217（191 aa）
|
Not recorded | NO3 NITRATE ION × 1 EDO 1,2-ETHANEDIOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；40%(v/v) Ethylene glycol, 20 %(w/v) PEG 8000, 0.3M Sodium nitrate, 0.3M Ammonium sulfate, 100mM Sodium HEPES/MOPS pH 7.5
|
Resolution 1.80 Å R-free 0.223 |
| 7D6Y eIF4E in Complex with a Disulphide-Free Autonomous VH Domain Deposited 2020-10-02 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；289 K；25% (w/v) PEG 6000, 0.01-02 M Ammonium Sulphate, 100mM Tris, pH 8.5
|
Resolution 1.67 Å R-free 0.206 |
| 7D8B Engineering Disulphide-Free Autonomous Antibody VH Domains to modulate intracellular pathways Deposited 2020-10-07 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；0.01M Tri-sodium citrate, 16% PEG 6000
|
Resolution 2.46 Å R-free 0.292 |
| 7D8B Engineering Disulphide-Free Autonomous Antibody VH Domains to modulate intracellular pathways Deposited 2020-10-07 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
1–217（217 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；0.01M Tri-sodium citrate, 16% PEG 6000
|
Resolution 2.46 Å R-free 0.292 |
| 7EZW Cyclic Peptide that Interacts with the eIF4E Capped-mRNA Binding Site Deposited 2021-06-02 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Potassium chloride 20% (w/v) PEG 3350
|
Resolution 2.35 Å R-free 0.248 |
| 7F07 Autonomous VH domain that interacts with eIF4E at the Capped mRNA Binding site. Deposited 2021-06-03 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；0.1 M TRIS.HCl pH 8.5 25% (v/v) PEG 550 MME
|
Resolution 2.25 Å R-free 0.266 |
| 7MEU A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders Deposited 2021-04-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–217（191 aa）
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 Z5D (2E)-2-{2-[4-([1,1'-biphenyl]-4-yl)-1,3-thiazol-2-yl]hydrazinylidene}-3-(2-nitrophenyl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；PEG 4000 10-20%, 100mM MES pH 6.5, 10% IPN
|
Resolution 1.91 Å R-free 0.219 |
| 7MEU A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders Deposited 2021-04-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
27–217（191 aa）
|
Not recorded | MGP 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；PEG 4000 10-20%, 100mM MES pH 6.5, 10% IPN
|
Resolution 1.91 Å R-free 0.219 |
| 7XTP eIF4E in Complex with a Disulphide-Free Autonomous VH Domain Deposited 2022-05-17 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1M Sodium HEPES pH7.5, 25% PEG 6000
|
Resolution 1.83 Å R-free 0.259 |
| 7XTP eIF4E in Complex with a Disulphide-Free Autonomous VH Domain Deposited 2022-05-17 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–217（217 aa）
|
Not recorded | MGO [[(2R,3S,4R,5R)-5-(6-AMINO-3-METHYL-4-OXO-5H-IMIDAZO[4,5-C]PYRIDIN-1-YL)-3,4-DIHYDROXY-OXOLAN-2-YL]METHOXY-HYDROXY-PHOSPHORYL] PHOSPHONO HYDROGEN PHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1M Sodium HEPES pH7.5, 25% PEG 6000
|
Resolution 1.83 Å R-free 0.259 |
| 8QM4 Potential drug binding sites for translation initiation factor eIF4E Deposited 2023-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
36–217（182 aa）
Chain B
36–217（182 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 PGE TRIETHYLENE GLYCOL × 2 W5B 3-phenylphenol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；273 K；0.002M DTT, 40% PEG 400, 0.1M pH=7.5 HEPES/NaOH
|
Resolution 1.85 Å R-free 0.217 |
| 8QM5 Potential drug binding sites for translation initiation factor eIF4E Deposited 2023-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
36–217（182 aa）
Chain B
36–217（182 aa）
|
Not recorded | W4U 1-(4-chlorophenyl)cyclopentane-1-carboxylic acid × 2 PGE TRIETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；0.002M DTT
40% PEG 400
0.1M pH=7.5 HEPES/NaOH
|
Resolution 1.89 Å R-free 0.220 |
| 8QM6 Potential drug binding sites for translation initiation factor eIF4E Deposited 2023-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
36–217（182 aa）
Chain B
36–217（182 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 3 W2N (1~{S})-1-[4-(2-fluorophenyl)phenyl]ethanol × 2 W4B (1~{R})-1-[4-(2-fluorophenyl)phenyl]ethanol × 2 PEG DI(HYDROXYETHYL)ETHER × 1 PGE TRIETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.002M DTT
40% PEG 400
0.1M pH=8 Tris/HCl
|
Resolution 1.93 Å R-free 0.227 |
| 8QM7 Potential drug binding sites for translation initiation factor eIF4E Deposited 2023-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
36–217（182 aa）
Chain B
36–217（182 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 3 PGE TRIETHYLENE GLYCOL × 1 W5K (2~{R})-2-[(1~{R})-1-[4-(2-fluorophenyl)-2-(2-hydroxyethylamino)phenyl]propoxy]propan-1-ol × 2 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.002M DTT
38% PEG 400
0.1M pH=8 Tris/HCl
|
Resolution 2.19 Å R-free 0.240 |
| 8QM8 Potential drug binding sites for translation initiation factor eIF4E Deposited 2023-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
36–217（182 aa）
Chain B
36–217（182 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 6 PGE TRIETHYLENE GLYCOL × 1 W4K (2~{R})-2-[(1~{S})-1-[4-(2-fluorophenyl)-2-(2-hydroxyethylamino)phenyl]propoxy]propan-1-ol × 2 DMS DIMETHYL SULFOXIDE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；10% PEG 3350
0.1M pH=8 Bicine/NaOH
|
Resolution 1.58 Å R-free 0.202 |
| 8QM9 Potential drug binding sites for translation initiation factor eIF4E Deposited 2023-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
36–217（182 aa）
Chain B
36–217（182 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 3 PEG DI(HYDROXYETHYL)ETHER × 4 DMS DIMETHYL SULFOXIDE × 2 W4K (2~{R})-2-[(1~{S})-1-[4-(2-fluorophenyl)-2-(2-hydroxyethylamino)phenyl]propoxy]propan-1-ol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.002M DTT
38% PEG 400
0.1M pH=8 Tris/HCl
|
Resolution 1.97 Å R-free 0.272 |
| 8SX4 Crystal Structure of eIF4e in complex with Compound 7n Deposited 2023-05-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
28–217（190 aa）
|
Not recorded | WXL [(~{Z})-4-[2-azanyl-7-[(5-chloranyl-1~{H}-indol-2-yl)methyl]-6-oxidanylidene-1~{H}-purin-9-yl]but-2-enyl]phosphonic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；16-26% Peg 3350, 0.1 M MES pH 6.0, 10% isopropanol and 2 mM CaCl2
|
Resolution 1.99 Å R-free 0.243 |
| 8SX4 Crystal Structure of eIF4e in complex with Compound 7n Deposited 2023-05-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
28–217（190 aa）
|
Not recorded | M7G 7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；16-26% Peg 3350, 0.1 M MES pH 6.0, 10% isopropanol and 2 mM CaCl2
|
Resolution 1.99 Å R-free 0.243 |
| 9DON Crystal structure of eIF4e in complex with Compound 5-PA Deposited 2024-09-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
28–217（190 aa）
|
Not recorded | M7G 7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；26% Peg 3350, 0.1 M MES pH 6.0, 10% isopropanol and 2 mM CaCl2
|
Resolution 2.09 Å R-free 0.247 |
| 9DON Crystal structure of eIF4e in complex with Compound 5-PA Deposited 2024-09-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
28–217（190 aa）
|
Not recorded | A1A8P 2-[3-[[2-azanyl-7-[(5-chloranyl-1-benzofuran-2-yl)methyl]-6-oxidanylidene-1~{H}-purin-9-yl]methyl]phenyl]ethylphosphonic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；26% Peg 3350, 0.1 M MES pH 6.0, 10% isopropanol and 2 mM CaCl2
|
Resolution 2.09 Å R-free 0.247 |
44 other PDB entries and 61 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | IF4E_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–217； UniProt 1–217 Author chain B； PDBConstruct 1–217； UniProt 1–217 Author chain C； PDBConstruct 1–217； UniProt 1–217 Author chain D； PDBConstruct 1–217； UniProt 1–217 |